Edition:
United Kingdom

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

7.72USD
4:32pm BST
Change (% chg)

$-0.18 (-2.28%)
Prev Close
$7.90
Open
$7.75
Day's High
$7.95
Day's Low
$7.67
Volume
26,473
Avg. Vol
14,013
52-wk High
$10.00
52-wk Low
$4.11

Latest Key Developments (Source: Significant Developments)

Ultragenyx And Arcturus Expand Existing Research License Agreement To Develop Additional Nucleic Acid Therapies For Rare Diseases
Wednesday, 19 Jun 2019 

June 19 (Reuters) - Arcturus Therapeutics Ltd ::ULTRAGENYX AND ARCTURUS THERAPEUTICS EXPAND EXISTING RESEARCH COLLABORATION AND LICENSE AGREEMENT TO DEVELOP ADDITIONAL NUCLEIC ACID THERAPIES FOR RARE DISEASES.ULTRAGENYX PHARMACEUTICAL INC - 30 MILLION OF UPFRONT PAYMENTS TO ARCTURUS, INCLUDING $6 MILLION CASH FOR COLLABORATION AGREEMENT AMENDMENT.ULTRAGENYX PHARMACEUTICAL INC - $30 MILLION OF UPFRONT PAYMENTS TO ARCTURUS, INCLUDING $24 MILLION EQUITY INVESTMENT AT $10 PER SHARE.ULTRAGENYX PHARMACEUTICAL INC - ULTRAGENYX BECOMES ARCTURUS' LARGEST SHAREHOLDER.ULTRAGENYX PHARMACEUTICAL - ARCTURUS IS ENTITLED TO PRECLINICAL, CLINICAL, REGULATORY, AND SALES MILESTONE PAYMENTS FOR PRODUCT DEVELOPED UNDER COLLABORATION.ULTRAGENYX PHARMACEUTICAL INC - KARAH PA KARAH PARSCHAUER, J.D., GENERAL COUNSEL OF CO, JOINING ARCTURUS' BOARD.ULTRAGENYX PHARMACEUTICAL - CERTAIN EARLY-STAGE MILESTONE PAYMENTS ARE REDUCED UNDER AMENDED LICENSE AGREEMENT.ULTRAGENYX PHARMACEUTICAL INC - CEO OF CO JOINING AS ARCTURUS BOARD OBSERVER.ULTRAGENYX PHARMACEUTICAL INC - UNDER AMENDED LICENSE AGREEMENT, TOTAL POTENTIAL MILESTONE PAYMENTS ARE INCREASED DUE TO EXPANDED NUMBER OF TARGETS..ULTRAGENYX PHARMACEUTICAL INC - ARCTURUS IS ALSO ENTITLED TO REIMBURSEMENT OF RELATED RESEARCH EXPENSES AND ROYALTIES ON COMMERCIAL SALES..ULTRAGENYX PHARMACEUTICAL - COS EXPANDED COLLABORATION TO DISCOVER & DEVELOP MRNA, DNA & SIRNA THERAPEUTICS FOR UP TO 12 RARE DISEASE TARGETS.  Full Article

Arcturus Therapeutics Q4 Loss Per Share $0.10
Monday, 18 Mar 2019 

March 18 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND YEAR END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.10.Q4 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA.APPOINTED ANDREW SASSINE AS CHIEF FINANCIAL OFFICER.FOR Q4 OF 2018, REPORTED REVENUE OF $7.6 MILLION, COMPARED WITH $2.0 MILLION DURING Q4 OF 2017.CASH, CASH EQUIVALENTS, AND INVESTMENTS TOTALED $36.7 MILLION AS OF DECEMBER 31, 2018.ARCTURUS THERAPEUTICS - BASED ON CURRENT PROJECTIONS, CO'S CURRENT CASH POSITION IS EXPECTED TO BE SUFFICIENT TO SUPPORT OPERATIONS THROUGH EARLY Q1 OF 2020.  Full Article

Arcturus Therapeutics Appoints Andrew Sassine As Chief Financial Officer
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS APPOINTS ANDREW SASSINE AS CHIEF FINANCIAL OFFICER.ARCTURUS THERAPEUTICS LTD - SASSINE HAS BEEN SERVING AS ARCTURUS' INTERIM CHIEF FINANCIAL OFFICER SINCE AUGUST 2018.  Full Article

Arcturus Therapeutics Appoints Four New Directors And Reaches Settlement Agreement With Founder Joseph E. Payne
Tuesday, 29 May 2018 

May 29 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS APPOINTS FOUR NEW DIRECTORS AND REACHES SETTLEMENT AGREEMENT WITH FOUNDER JOSEPH E. PAYNE.ARCTURUS THERAPEUTICS LTD - OTHER KEY TERMS OF SETTLEMENT AGREEMENT INCLUDE MUTUAL RELEASES OF ALL PARTIES.ARCTURUS THERAPEUTICS - OTHER KEY TERMS OF SETTLEMENT AGREEMENT INCLUDE AGREEMENT BY CO AND JOSEPH E. PAYNE TO TERMINATE ALL PENDING LITIGATION.ARCTURUS THERAPEUTICS - SETTLEMENT APPROVED ON MAY 28, 2018 BY ISRAELI DISTRICT COURT.  Full Article

Arcturus Therapeutics issues statement on extraordinary general meeting of shareholders
Tuesday, 27 Feb 2018 

Feb 26 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS - ‍CO SOUGHT TO APPOINT NEW INDEPENDENT AUDITOR IN ORDER TO REPORT FINANCIAL RESULTS, INCLUDING ITS FINANCIAL STATEMENTS FOR 2017​.ARCTURUS-‍IF APPOINTMENT OF AUDITORS FOR 2017 FINANCIAL STATEMENTS IS NOT APPROVED BY SHAREHOLDERS, LIKELIHOOD THAT REPORT WILL NOT BE FILED IN TIMELY MANNER.  Full Article

Joseph Payne Reports 13.7 Pct Stake In Arcturus Therapeutics
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - Arcturus Therapeutics Ltd ::JOSEPH PAYNE SAYS EMAILED LETTER DATED FEBRUARY 12, REQUESTED BOARD OF ARCTURUS THERAPEUTICS CONVENE EXTRAORDINARY GENERAL MEETING AS SOON AS POSSIBLE.JOSEPH PAYNE REPORTS 13.7 PERCENT STAKE IN ARCTURUS THERAPEUTICS LTD AS OF FEBRUARY 12 - SEC FILING.  Full Article

Certain Arcturus Therapeutics Shareholders Expressed Support For Former CEO Joseph Payne's Leadership
Tuesday, 6 Feb 2018 

Feb 6 (Reuters) - Arcturus Therapeutics Ltd ::FORMER CEO JOSEPH PAYNE SAYS HE WAS APPROACHED BY CERTAIN ARCTURUS THERAPEUTICS SHAREHOLDERS, WHO EXPRESSED SUPPORT FOR HIS CONTINUED LEADERSHIP.FORMER CEO PAYNE SAYS INTENDS TO DISCUSS WITH SUPPORTING SHAREHOLDERS POTENTIAL CHANGES TO COMPOSITION OF ARCTURUS THERAPEUTICS BOARD, MANAGEMENT.FORMER CEO PAYNE SAYS INTENDS TO DISCUSS WITH SUPPORTING SHAREHOLDERS HIS IMMEDIATE REINSTATEMENT AS PRESIDENT AND CEO OF ARCTURUS THERAPEUTICS.FORMER CEO JOSEPH PAYNE REPORTS A 13.7 PERCENT STAKE IN ARCTURUS THERAPEUTICS AS OF NOVEMBER 16, 2017 - SEC FILING.FORMER CEO PAYNE - TO DISCUSS WITH SUPPORTING SHAREHOLDERS CHANGES INCLUDING ELECTION OF NEW DIRECTORS TO REPLACE ARCTURUS THERAPEUTICS' BOARD MEMBERS.  Full Article

Arcturus and Curevac Enter Into Strategic Collaboration To Jointly Novel Messenger RNA Therapeutics
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Arcturus Therapeutics Ltd ::CO, CUREVAC AG ENTER INTO STRATEGIC COLLABORATION TO JOINTLY DISCOVER, DEVELOP,COMMERCIALIZE NOVEL MESSENGER RNA THERAPEUTICS.DEVELOPMENT COSTS WILL BE SHARED BETWEEN COS,WITH PLANS TO CO-COMMERCIALIZE PRODUCTS IN FUTURE UNDER PROFIT SHARING ARRANGEMENT.  Full Article

Arcturus Therapeutics Ltd Says Raised About $67.8 Million In Equity Financing
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS LTD SAYS RAISED ABOUT $67.8 MILLION IN EQUITY FINANCING .  Full Article

Alcobra qtrly ‍net loss per share $0.09​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Alcobra Ltd :Alcobra announces third quarter 2017 financial results and provides corporate update.Alcobra Ltd - qtrly ‍net loss per share $0.09​.  Full Article